Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have received a consensus rating of “Moderate Buy” from the fifteen analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $17.40.

Several analysts have weighed in on the stock. Wall Street Zen cut shares of Alphatec from a “buy” rating to a “hold” rating in a research note on Sunday, October 11th. TD Cowen increased their target price on shares of Alphatec from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Stephens started coverage on shares of Alphatec in a research report on Thursday, July 23rd. They set an “overweight” rating and a $15.00 target price on the stock. Stifel Nicolaus lowered their target price on shares of Alphatec from $16.00 to $13.00 and set a “buy” rating on the stock in a report on Wednesday, July 8th. Finally, UBS Group lifted their price target on shares of Alphatec from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th.

Insider Activity at Alphatec

In related news, General Counsel Tyson Marshall sold 8,168 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $9.65, for a total transaction of $78,821.20. Following the sale, the general counsel owned 630,398 shares of the company’s stock, valued at $6,083,340.70. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Patrick Miles acquired 115,000 shares of the stock in a transaction on Thursday, September 10th. The shares were bought at an average price of $8.81 per share, for a total transaction of $1,013,150.00. Following the purchase, the chief executive officer owned 5,893,551 shares in the company, valued at approximately $51,922,184.31. This trade represents a 1.99% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 13.48% of the company’s stock.

Institutional Trading of Alphatec

Large investors have recently bought and sold shares of the business. Rhenman & Partners Asset Management AB raised its position in Alphatec by 11.1% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 20,000 shares of the medical technology company’s stock worth $421,000 after purchasing an additional 2,000 shares during the last quarter. Diversified Trust Co increased its position in Alphatec by 17.6% in the 1st quarter. Diversified Trust Co now owns 14,876 shares of the medical technology company’s stock valued at $162,000 after buying an additional 2,227 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Alphatec by 4.2% during the first quarter. SG Americas Securities LLC now owns 67,065 shares of the medical technology company’s stock worth $730,000 after purchasing an additional 2,675 shares during the period. Summit Securities Group LLC acquired a new position in Alphatec during the first quarter worth $29,000. Finally, Valeo Financial Advisors LLC lifted its position in Alphatec by 7.2% in the 2nd quarter. Valeo Financial Advisors LLC now owns 44,363 shares of the medical technology company’s stock valued at $384,000 after acquiring an additional 2,967 shares in the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Price Performance

NASDAQ ATEC traded down $0.47 on Friday, reaching $10.46. The stock had a trading volume of 2,702,778 shares, compared to its average volume of 2,110,214. The firm has a fifty day moving average of $9.93 and a two-hundred day moving average of $9.41. Alphatec has a 1-year low of $6.82 and a 1-year high of $23.29. The company has a market cap of $1.62 billion, a P/E ratio of -14.73 and a beta of 0.78.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Tuesday, August 4th. The medical technology company reported $0.07 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.07. Alphatec had a negative net margin of 13.49% and a negative return on equity of 6,752.24%. The company had revenue of $213.51 million during the quarter, compared to analysts’ expectations of $211.26 million. During the same quarter in the previous year, the business posted $0.02 earnings per share. Alphatec’s quarterly revenue was up 15.1% on a year-over-year basis. Research analysts predict that Alphatec will post -0.45 EPS for the current fiscal year.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the surgical treatment of spinal disorders. Through its Alphatec Spine business, the company develops and markets implants, biologics, instruments and procedural technologies designed to support spine surgery and improve patient outcomes.

Its product portfolio includes systems for spinal fusion and reconstruction, including interbody implants, fixation devices and navigation or imaging-enabled surgical solutions.